Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT01281917 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT01281917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01281917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
June 30, 2014
Enrollment
40 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkins lymphoma